Cost-Effectiveness Analysis of Abrocitinib Compared with Other Systemic Treatments for Severe Atopic Dermatitis in Spain.
Rosa María Romero JiménezPedro Herranz PintoMinia Campos DomínguezSusana Aceituno MataAlba BellmuntMiriam PradesDaniel ArumiIrene Hernández-MartínValeria Herrera-LassoNoelia LlevatAlfonso De Lossada JusteFrancisco Jose Rebollo LasernaPublished in: PharmacoEconomics - open (2024)
The results of the study show that abrocitinib is a cost-effective therapy compared with other JAK inhibitors and biological therapies from the Spanish NHS perspective.
Keyphrases